The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Combined acalabrutinib treatments for CLL
Jennifer Woyach, MD, Ohio State University College of Medicine, Columbus, OH, discusses the two-year follow-up of a study (NCT02296918) aiming to evaluate the efficacy and safety or acalabrutinib combined with venetoclax and obinutuzumab or rituximab in both treatment-naïve and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients. This line of therapy was well tolerated among all patients, with very few and mostly mild adverse events being reported. At the time of the data cut-off, all patients remain progression-free and on therapy. High rates of MRD negativity were also observed. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
